Tarsadia Capital employs a flexible, long-duration investment mandate across public and private equities and commodities globally, utilizing a multi-strategy approach that includes venture and growth equity, life sciences, and real estate. The firm is thesis-driven, seeking to partner with companies from Series A and beyond that are tackling systemic problems in large markets, often focusing on sectors like Healthtech, Fintech, DeepTech, and Life Sciences.
They made 2 investments in the last 12 months. Average disclosed round size is $160.8M (across 5 rounds with reported amounts).
Portfolio
7
Fund Size
$2B
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CClinTrial Research | Growth | — | Dec 2025 |
| MMatterworks, Inc. | Series A | — | Jun 2025 |
| CChronus Health | Series A | $22M | Jan 2022 |
 Yieldstreet | Series C | $100M | Jun 2021 |
| JJüsto | Series B | $152M | — |
| DDaqri | Series D | $275M | — |
 Creditas | Series E | $255M | — |
Top Co-Investors
General Atlantic1 shared
Foundation Capital1 shared
Quiet Capital1 shared
Pillar VC1 shared
Germin81 shared
LGT Lightstone1 shared
e.ventures1 shared
Sunley House Capital1 shared
Monta Vista Capital1 shared
SOSV1 shared
Kingfisher Investment Advisors1 shared
Top Tier Capital Partners1 shared
Gaingels1 shared
Edison Partners1 shared
Soros Fund Management1 shared
Greenspring Associates1 shared
The Raine Group1 shared
Greycroft1 shared
Last updated: 6 March 2026